Market Access News | pharmaphorum

News

Innsena backs CancerX’s digital drive to improve access

Healthtech consultancy Innsena has committed funding and expertise to The White House’s CancerX initiative, launched last year to encourage the use of digital technologies

News

First drug therapy for frostbite has been cleared by FDA

People at risk of losing a finger or toe to frostbite now have the first FDA-approved treatment that could prevent a life-changing amputation.

News

UK patients very concerned about access to diagnostics

Almost two-thirds of patients in the UK would consider paying for diagnostics out of pocket if they face a long wait for free NHS testing, and almost all want to see more

News

Onivyde gets ‘practice-changing’ FDA OK in pancreatic cancer

Ipsen has won FDA approval for first-line use of its pancreatic cancer therapy Onivyde, saying it is now part of a potential new “standard-of-care” for patients.

News

Biogen’s Skyclarys is first EU drug for Friedreich’s ataxia

After getting a green light from the European Commission, Biogen’s Skyclarys is the first approved medicine for the inherited neurological disease Friedreich’s ataxia (FA)

News

FDA changes its mind and approves Takeda’s Eohilia

In its second attempt, Takeda has secured FDA approval for Eohilia, which becomes the first and only oral therapy in the US for eosinophilic oesophagitis (EoE).

Innsena backs CancerX’s digital drive to improve access

First drug therapy for frostbite has been cleared by FDA

UK patients very concerned about access to diagnostics

Onivyde gets ‘practice-changing’ FDA OK in pancreatic cancer

Biogen’s Skyclarys is first EU drug for Friedreich’s ataxia

FDA changes its mind and approves Takeda’s Eohilia

FDA orders blindness risk warning to GLP-1 agonist labels

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks